Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07531745 · ClinicalTrials.gov registry record · Phase 1
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07531745 is a Phase 1 study that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT07531745, a Phase 1 study, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
Interventions
- DRUG ION337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07531745
The ClinicalTrials.gov registry entry for NCT07531745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ION337 is the first listed.
NCT07531745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07531745 about?
NCT07531745 is a clinical study titled "ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome". The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
What is the current status of trial NCT07531745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-05-21. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07531745?
The interventions under investigation include: ION337 (DRUG).
Who is sponsoring clinical trial NCT07531745?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.